Nautilus Biotechnology (NAUT) Non Operating Investment Income (2020 - 2021)

Nautilus Biotechnology (NAUT) posted Non Operating Investment Income of $10982.0 for Q1 2021, down 79.26% sequentially from $52952.0 in Q4 2020.

Nautilus Biotechnology (NAUT) Non Operating Investment Income (2020 - 2021) Analysis & Trends

Nautilus Biotechnology has reported Non Operating Investment Income for 2 years, with the latest figure at $10982.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	-
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Nautilus Biotechnology	114.43 Mn	114.43 Mn	175,000.00	-

Download Data